TMDX— AI Stock Forecast & Price Targets
Published 6/19/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TMDX price forecast →
TransMedics is a high-quality medical device franchise with a dominant OCS platform driving 30% TTM revenue growth and 45% ROE, but the stock has been cut in half from $156 to ~$79 amid margin compression, heavy capex, and a Q1'26 free cash flow reversal. With shares trading at ~16x trailing earnings vs. analyst target of $119 and Kronos forecasting near-term upside to ~$95, the risk/reward is asymmetric to the upside — but elevated short interest (22%) and decelerating operating margins demand a measured accumulation approach rather than a full commitment.
1-4 week view: tactical accumulate. Stock has broken above SMA20 and Kronos points to $94 forecast vs. current ~$79. Initiate or add half-size on any dip to $73-75 (recent breakout retest), with stop below $68. Target first scale-out at $88-92. Invalidation: weekly close below $70 reopens the door to retest the $60 low.
1-6 month view: constructive. Base case is a re-rating toward the $95-110 zone as the market digests the Q2/Q3 2026 earnings (next print May 5 cycle) and looks for evidence that operating margin troughed in Q1'26. Expected return range +20% to +40%. Catalysts: margin stabilization, OCS Heart/Liver volume disclosures, any update on the National OCS Program economics. What changes my mind: a second consecutive quarter of operating margin below 10%, or FCF remaining negative into Q2'26.
1-3 year view: TransMedics is the category-defining platform in ex-vivo organ perfusion with a wide moat (OCS Heart/Lung/Liver + logistics network) and a TAM that should expand as DCD organ utilization grows. Sales have compounded ~86-88% over the past 3-5 years and a more normalized 20-25% CAGR seems achievable. The Kronos weekly forecast warning of a decline toward $57 by 2028 reflects the biggest structural risk: competitive entry (Paragonix, OrganOx, Bridge to Life) and reimbursement compression on the logistics business as it scales. If management executes, $150-180 is reasonable in 2-3 years; if competition compresses margins, the stock could revisit $60.
Revenue trajectory remains strong with TTM sales of $635.9M (+30.2% Y/Y) and Q1'26 revenue of $173.9M (+21.2% Q/Q growth trend), but the quality of growth is deteriorating. Operating margin compressed from 23.2% in Q2'25 to just 7.6% in Q1'26, and operating income fell from $36.6M to $13.3M over the same span — a clear signal that platform expansion investments (the Zacks article flagged this exact concern) are outpacing leverage. The balance sheet shows $461.7M cash against $863.4M debt (D/E of 1.75), with total debt having ballooned from $519M in late 2025 to $863M in Q1'26, suggesting a recent capital raise or convertible issuance. Free cash flow turned negative (-$12.1M) in Q1'26 after generating $82.5M in Q2'25, driven by a $36.7M capex quarter (up 4x sequentially). On the positive side, gross margin remains healthy at 58-61%, ROE is exceptional at 45.2%, current ratio of 6.74 is fortress-like, and TTM profit margin is 27%. The setup: a fundamentally sound franchise going through an investment cycle that is temporarily depressing operating metrics.
Across timeframes the picture is mixed but tilting constructive. The 1d chart shows a brutal drawdown from ~$148 in March to a $60 low in May, followed by a sharp V-recovery to $78.79 — the stock is -36.5% vs SMA200 but +3.2% above SMA20, indicating a nascent trend reversal. RSI of 46 is neutral with room to run. The 4h chart shows the recovery rally has retraced roughly half the prior drop. On the 1h chart, Kronos forecasts the next leg up to ~$94.5 with peaks near $100 — aligning with the analyst consensus target of $119.10 and Stifel's recent $80 PT raise. The weekly Kronos forecast is more cautious, showing strength into late 2026/early 2027 followed by a meaningful decline toward $56.7 by mid-2028, which mirrors typical med-tech cyclicality after capex-heavy build-outs. Key levels: support $72-75 (recent breakout zone), then $60 (52-week low); resistance $85, then $95-100 (forecast cluster), then $119 (analyst target).
News flow is incrementally positive but measured. Stifel raised its price target from $75 to $80 on June 18 while maintaining a Hold — a constructive but unenthusiastic call. The Simply Wall St. piece (June 6) reinforces the structural bull narrative around the OCS platform's role in transforming organ transplant therapy and highlights strong ROE. The Zacks note (May 28) explicitly flags the key tension in the story: OCS platform momentum vs. margin pressure from expansion investments — which the Q1'26 financials directly confirm. There are no negative catalysts (FDA issues, competitive losses, guidance cuts) in the feed. Broader market news is noise for this name. Net: the news supports the 'good company in an investment cycle' framing rather than offering any sharp directional catalyst.
- OCS platform expansion across Heart, Lung, and Liver — all three modalities now commercial, with Q1'26 revenue of $173.9M reflecting continued multi-organ adoption
- National OCS Program scaling — turnkey outsourced organ retrieval service driving the surge in capex ($36.7M in Q1'26) and logistics/aviation infrastructure build-out
- DCD (donation-after-circulatory-death) heart program — a structurally underpenetrated organ pool where OCS is the enabling technology
- International expansion — company describes US + international footprint, with infrastructure investments likely supporting EU/APAC ramp
- Stifel PT raise to $80 (June 18) signals sell-side willingness to mark estimates higher as visibility improves
- Operating margin collapse from 23.2% (Q2'25) to 7.6% (Q1'26) — if this is structural rather than investment-cycle related, the valuation re-rates lower
- Free cash flow turned negative -$12.1M in Q1'26 after $82.5M positive in Q2'25; capex jumped 4x sequentially
- Debt load expanded from $519M to $863M in one quarter, with D/E at 1.75 — leverage risk if FCF doesn't recover
- Short interest at 22.04% of float ($7.36M shares) signals significant skeptic crowding; can squeeze either way
- EPS Q/Q declined -71.22% — earnings volatility hurts multiple compression risk
- Kronos weekly forecast projects decline to ~$57 by mid-2028, consistent with competitive/cyclical risk to the logistics business
- Forward P/E of 23.9 vs trailing 16.8 implies EPS is expected to decline, suggesting consensus is already cutting numbers
- Beta of 1.88 means broad market drawdowns will be amplified
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord